Ever wondered what it'd be like to run a de novo antibody campaign against 100 of the hardest targets, simultaneously, with 76% success rate, and have the complete wetlab validated results days from the project's start? We show you what that looks like, too: www.jurabio.com/mesa

JURA is launching a new target intelligence dashboard called MESA jurabio.com/mesa with a nice interactive case study from our recent TCRm campaigns. Go check it out -- we'll open to crowd-sourced targets soon. @jura.bsky.social

For most of the history of molecular biology, the experimental bottleneck has been so severe that we've learned to work around it rather than through it. The workaround is prediction. If you can only physically test a small number of molecules, you need to be good at guessing which ones to make.

We are at the #StartupVillage at #EurIPS today — come say hi 👋 @jura.bsky.social

The race to first-in-human is accelerating globally. The obvious response is to scale up: more automation, more cells, more sequencing, more capital. This will until it doesn't. At @jura.bsky.social we've been building approaches beyond the obvious.

Our LeaVS preprint is up! We demonstrate empirically & prove theoretically that LeaVS can dramatically accelerate learning, increasing the effective dataset size by orders of magnitude. Really useful biological assays have intractable bottlenecks: make the most of what you can get. @jura.bsky.social

For every Nobel that goes to a criminally under-recognized woman scientist (Brunkow, Karikó), or fails to go (Candy Lee), a week of mourning and reform for an academic system wherein you can do Nobel-prize-worthy-work and still end up without a conceivable path to being a professor.

Let's say all of a sudden you found yourself with 100,000+ wetlab validated, de novo AI designed, fully human GLP1R binding antibodies? Could you turn the patent suite into a financial instrument? Anyone who thinks about this you could connect me to?

How do you train AI on protein data when functional sequences are astonishingly rare? Traditional iterative optimization fails because most measurements show zero. Our newly announcing learning system, LeaVS, shows a way.

A fundamental lesson of modern AI is that scale is essential: training bigger models on bigger datasets unlocks new capabilities. A fundamental lesson of AI engineering is that scaling up isn't trivial: it is not just a matter of spending more money and resources.

🚨 One week left to apply! I am hiring a fully funded PhD fellow and a postdoc to work on membrane protein structural biology and pharmacology at Univ Copenhagen Come work with a great team and exciting projects in a collaborative environment! 🔗 Links to the ads in comments #CryoEM #AcademicJobs

I'm looking for my first PhD student! We will push the frontiers of probabilistic machine learning for the molecular sciences, and study how to design new algorithms that exploit the unique properties of molecular systems to learn about the world. efzu.fa.em2.oraclecloud.com/hcmUI/Candid...

Want to work at the frontier of active learning and AI-guided experimentation? @eliweinstein.bsky.social is hiring PhD students at @dtu.dk DTU Chemistry. Full job link: efzu.fa.em2.oraclecloud.com/hcmUI/Candid... Thanks for re-sharing widely!

Totally agree that standard biological data isn't built for AI. We need to think strategically about how we build better, less biased richer datasets specifically for machine learning

Thrilled to demonstrate VISTA, our platform for creating high quality, AI-ready biological data loops at massive scale!

Great coverage of VISTA by the wonderful @faylinphd.bsky.social over at GEN: www.genengnews.com/topics/artif... Read about VISTA: www.jurabio.com/blog/vista

When AI drives your data generation, learning is more efficient and effective. Take a deep dive into VISTA:

So excited about this - we did iterative generative design at large scale with variational synthesis, and got human scFv candidates against some of the hardest therapeutic targets around.

The biggest challenge for AI in biology isn't just models, it's the data used to train them. Standard biological data isn't built for AI. To unlock generative AI for drug discovery, we must rethink how we generate and capture data. 1/

We can make population genetics studies more powerful by building priors of variant effect size from features like binding. But we’ve been stuck on linear models! We introduce DeepWAS to learn deep priors on millions of variants! #ICML2025 Andres Potapczynski, @andrewgwils.bsky.social 1/7

This week is the BIO conference in Boston's Seaport. If you are in town for it and are interested in meeting to learn more about @jura.bsky.social please feel free to send a DM! Would love to see you.

“The search is on for 25 researchers from around the world in Lund University’s largest ever international recruitment drive. The main focus will be on AI research and other areas in which the University has a strategic focus.” www.lunduniversity.lu.se/article/lund...

I think we’ve now manufactured more AI drug designs than OpenAI has generated responses, but plenty of bottlenecks remain to be innovated upon ‘til delivering the safest and most effective therapeutic is as easy as clicking print. DM if you’re interested in joining us at @jura.bsky.social.

If I was applying for PhD positions, Eli’s group would be at the top of my list.

I couldn't be more excited to be moving to Copenhagen in the fall with @eweinstein.bsky.social as he joins @dtu.dk as an assistant professor of chemistry. @jura.bsky.social wilI add one more to our sites in Boston, Basel and Oslo. If you're building a startup in CPH I'd love to hear from you!

We are looking for someone to join the group as a postdoc to help us with scaling implicit transfer operators. If you are interested in this, please reach out to me through email. Include CV, with publications and brief motivational statement. RTs appreciated!

Don’t upload other people’s confidential manuscripts or grants to third party tools without permission.

If there's such a thing as AI for drug design & development on easy mode, then it's probably in being able to build and test every design. Check out our journey to the 10 quadrillion AI-designed antibody library now; we're going to be sharing some big updates soon: ▶️ www.jura.bio/blog/variati...

This Thursday, 1PM, @eweinstein.bsky.social is headed back to CMU, this time to the Machine Learning Department. He'll be sharing his work on hierarchical causal models. If you're on campus, I encourage to you check it out! www.ml.cmu.edu/calendar/

Tomorrow -- another chance to learn about variational synthesis, probabilistic experimental design methods, & ways to capture scaled functional data for model training: this time with zoom access for those of you remote, 1pm at @cmu.edu Computer Science. Details at: www.cs.cmu.edu/calendar/181...

Today at UPenn's CIS Seminar: a chance to hear about variational synthesis, probabilistic experimental design methods, and ways to capture modern ML-scale functional data for biology: events.seas.upenn.edu/event/13596/

Aithyra is hiring! We are looking for multiple starting PIs in life sciences and AI/ML. We offer highly competitive packages and salaries among the highest in Europe. www.oeaw.ac.at/aithyra/news...

⏰ Two weeks left to register for our Benzon Symposium on Protein structure prediction and design 🧶🧬🖥️ Meeting will take place in Copenhagen 🇩🇰 on Sept. 1–4, 2025, and will feature an amazing list of speakers 👨‍🔬👩‍🔬👩‍💻👨‍💻 Submit your application via: benzon-foundation.dk/benzon-sympo...

I had a fantastic time presenting at the Future of Care Conference this weekend at Rockefeller -- besides getting to present @jura.bsky.social's biologics development platform, VISTA, which allows us to rapidly and reliably develop clinical-outcome-based biologics against targets with acute need,

Excited to be one of the keynote speakers at this weekend's Future of Care 2025 conference, hosted at The Rockefeller University in NYC. If you're in town, it would be wonderful to see you there! Details in comments.

This Thursday, @eweinstein.bsky.social is traveling to the University of Chicago to give a joint Statistics & Data Science colloquium. If you've been interested in learning more about #variationalsynthesis and are local, I encourage you to attend! Event link: stat.uchicago.edu/events/event...

Tuesday at noon at @upenn.edu, @eweinstein.bsky.social will present on #variationalsynthesis and other experimental design systems. www.bio.upenn.edu/events/2025/...

🔎 Asking for a friend (really): What are the best health-tech/diagnostics incubators out there? US-focussed but world-wide is okay, too. First-time entrepreneur with lots of Pharma experience is looking to get started building and wants to do so in that kind of environment.

I'll be attending my first ever #JPM this January. Please reach out if you will be there, too, and are interested in meeting up, or have suggestions for events I should attend. I'm not eager to cross the picket line of striking SF hotel workers -- any ideas for accommodation? Would Palo Alto work?

At the Danaher AI Summit in SF. Something I learned — in the 1948 Declaration of Human Rights? The right to the benefit of the proceeds of science.

Excited to see a lot of our team joining 🦋! If you're interested in following them, you can find them at: @lizbwood.bsky.social @eweinstein.bsky.social @mgollub.bsky.social @highvariance.bsky.social Plus our scientific advisor: @lestermackey.bsky.social Hopefully many more to come!

Looking forward to this event tomorrow. It's been so wonderful visiting Basel so far: it probably won't come as a surprise, but the city is really gorgeous and with wonderful trams. Here are two pictures from the university's botanical gardens as the sun was setting.

New @jura.bsky.social merch dropped today! Dm to reserve yours. Very generous one-size-fits-all.

I feel lucky that I get to travel to Basel next week and see @jura.bsky.social's European HQ for the first time in person. This event is already sold out, but please let me know if you're based in Switzerland and would like to meet up while I'm in town -- both Basel and Zurich!

Tomorrow in Baltimore, head to the Johns Hopkins University Computer Science Department Seminar Series for more on #VariationalSynthesis with @eweinstein.bsky.social. Full details: www.cs.jhu.edu/event/cs-sem...

Thanks to those of you who have recently followed me! I am beginning to suspect I made it onto a starter pack somewhere. Please don't hesitate to give a 👋 if you'd like me to follow you right away; otherwise, I'm slowly working my way through all the new additions! It's a pleasure to see you here.

Interesting preprint on the nuances of reductionism and causal inference (with obvious implications for single-cell genomics): arxiv.org/abs/2401.05330

Today (Nov 12) is the last day to apply to the #TermeerFellows program. If you are a first-time founder building a patient-focussed company, I couldn't recommend the program, or its surrounding community, more highly. Here's the link: termeerfoundation.slideroom.com#/login/progr... Qs? DM me.